Cytoclonal Pharmaceutics Inc. And Bristol-Myers Squibb Sign $2 Million R&D Agreement Extension
"Bristol-Myers Squibb is pleased with the development of Cytoclonal's new technology and looks forward to further progress," said David R. Dodds, Ph.D., Director of Fermentation and Biocatalysis Development, Bristol-Myers Squibb.
"We look forward to continued advancement of our program with Bristol-Myers Squibb, a worldwide leader in the field of cancer therapeutics," said Dr. Arthur P. Bollon, President and Chief Executive Officer of Cytoclonal.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.